Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma

SIMPLE SUMMARY: Patients with unresectable hepatocellular carcinoma (HCC) who receive lenvatinib treatment often lose their appetite, which leads to poor outcomes, but the reason for appetite loss is unclear. FGF21 is a natural hormone-like factor that modulates appetite. We investigated the effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohya, Risako, Suda, Goki, Ohara, Masatsugu, Sasaki, Takashi, Yoda, Tomoka, Sakurai, Naofumi, Yoshida, Sonoe, Fu, Qingjie, Yang, Zijian, Hosoda, Shunichi, Maehara, Osamu, Ohnishi, Shunsuke, Tokuchi, Yoshimasa, Kitagataya, Takashi, Suzuki, Kazuharu, Kawagishi, Naoki, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Ogawa, Koji, Sakamoto, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296590/
https://www.ncbi.nlm.nih.gov/pubmed/37370867
http://dx.doi.org/10.3390/cancers15123257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296590/
https://www.ncbi.nlm.nih.gov/pubmed/37370867
http://dx.doi.org/10.3390/cancers15123257

Ejemplares similares